My latest acquisition

A small "Diet Brick" soda machine made out of Legos

 My son informs me that this is an “illegal build” but I like it anyway.

from Blogger http://tushnet.blogspot.com/2024/04/my-latest-acquisition.html

Posted in Uncategorized | Tagged | Leave a comment

failure to properly allege falsity dooms FedEx at 6th Circuit

Fedex Ground Package
System, Inc. v. Route Consultant, Inc., No. 23-5456, — F.4th —-, 2024 WL
1364707 (6th Cir. 2024)

The court of appeals
affirmed the dismissal
of FedEx’s false advertising claims
(under the Lanham Act and Tennessee
Consumer Protection Act), albeit on somewhat different grounds. The district court had focused on FedEx’s harm story; the court of appeals turns on falsity.

FedEx (here called
FXG) alleged that Route Consultant made disparaging statements to foster
discontent between FXG and its contractors, which would damage FXG and benefit
Route Consultant.

FXG doesn’t deliver
packages directly; it has a network of independent service providers
(confusingly for me, ISPs) that provide pickup and delivery within neighborhoods,
and transportation service providers (TSPs). Collectively they’re called
“contracted service providers” (CSPs).

Spencer Patton owns
several ISPs that work with FXG and also owns Route Consultant, a consultancy
business for current CSPs and those that are looking to get into the business.
Route Consultant advises CSPs on “buying and selling FXG routes, ISP and TSP
ownership and operations, and fleet strategy.” It also provides brokerage
services for CSPs interested in selling their business or otherwise assigning
their CSP contracts, and it provides instructional courses and programs for
CSPs.

FXG asserts that
Route Consultant launched a promotional campaign premised on a “fictionalized
crisis” between FXG and its CSP network, claiming that the CSPs were
“financially collapsing under the weight of … dramatic cost changes”
resulting from global economic trends, and that these changes had “gone
unaddressed by FXG in 2022.”. The alleged aim was to motivate CSPs to
renegotiate their contracts with FXG, which would in turn allow Route
Consultant to position itself as the intermediary for the renegotiations.

FXG identified nine
specific claims relating to FXG’s alleged failure to make financial adjustments,
including that the “average FXG business run by a CSP currently operates on
profit margins below 0%”; “the current CSP financial model is collapsing due to
substantial increases in the cost of fuel, labor, and vehicles over the past 12
months”; pointing to “soaring levels of CSP default rates as evidence of the
current financial stress within the network”; and “Almost all of the other
contractors that had renegotiation requests were also denied.”

For purposes of a
motion to dismiss, “a complaint may not baldly assert that a challenged
statement is false or misleading. It must explain why and how it is so.”

Statements that FXG
had made “no financial adjustments” for CSPs: These were factual claims, but not
plausibly alleged to be literally false. The complaint alleged literal falsity
because “ISPs [ ] requested mid-contract renegotiations for only about 10% of
their agreements in 2022; FXG has consented to approximately 40% of
renegotiation requests since July 1, 2022; and over 90% of those renegotiations
led to agreement on new terms that resulted in higher contractual payments to
the ISPs.” But, in the context in which they were made, Route Consultant was
not describing a failure to make financial adjustments on an individualized
basis, but contrasting the “flat, across-the-board” CSP pay increases that FXG
made in 2020 “in order to overcome the extraordinary conditions of” the
COVID-19 pandemic and also asserting that FXG refused to properly address the
issues raised by a “group of FedEx contractors” who wrote letters of concern. “The
surrounding context of the statements makes no mention of individual
renegotiation requests being denied.”

On a motion to
dismiss, only “reasonable inferences” are drawn in the plaintiff’s favor. “And
under the circumstances present here, it would be unreasonable to divorce [the
statements] from their context.” Without literal falsity, the complaint didn’t
allege misleadingness.

Statements that the
“average FXG business run by a CSP currently operates on profit margins below 0%”
and that “since [ ] Q4 of 2020, the industry has seen ‘a 15% pullback on the
value of routes ….’” These were also statements of fact, but the complaint didn’t
actually plead that they were false or misleading. Alleging that these
businesses generated an operating margin of 16%, based on FXG’s calculations
from Route Consultant’s appendix, didn’t go to profit
margin. Likewise,
alleging that an “industry analyst …
noted that ‘these ISP businesses are being sold for an average multiple of 0.8x
Sales and over 2x their fleet value’ ” does not “explain how the sales value of
an ISP at one point in time demonstrates whether there has been a ‘pullback’ in
a route’s value over a period of time.”

Financial model
collapsing/soaring levels of CSP default rates: These were not statements of
fact but loose, hyperbolic terms. Even if “soaring” just meant rising, FXG didn’t
plead falsity, “because its complaint refers only to the financial health of
ISPs, not CSPs, and says nothing about defaults at all.” Anyway, collapsing/soaring
couldn’t be measured to be falsified.

“Almost all of the
other contractors that had renegotiation requests were also denied.” This was a
statement posted in August 2022; the allegation that “FXG has consented to
approximately 40% of renegotiation requests since July 1, 2022; and over 90% of
those renegotiations led to an agreement on new terms that resulted in higher
contractual payments” did not make this statement literally false, because it
wasn’t limited to the period starting in July 2022; in context, it referred to
requests over the past year and was not “unambiguously deceptive.”

from Blogger http://tushnet.blogspot.com/2024/04/failure-to-properly-allege-falsity.html

Posted in Uncategorized | Tagged | Leave a comment

The People’s Joker

 Interesting NYT story, in which I am quoted.

from Blogger http://tushnet.blogspot.com/2024/04/the-peoples-joker.html

Posted in Uncategorized | Tagged | Leave a comment

Podcast on Bass Notes and Base Rates

 I’m on Excited Utterance with Ed Cheng discussing my article with Chris Buccafusco.

from Blogger http://tushnet.blogspot.com/2024/04/podcast-on-bass-notes-and-base-rates.html

Posted in Uncategorized | Tagged , , | Leave a comment

Gerber’s Good Start troubles continue

Hasemann v. Gerber
Prods. Co., 2024 WL 1282368, No. 15-CV-2995(EK)(JAM), 16-CV-1153(EK)(JAM),
17-CV-0093(EK)(JAM) (E.D.N.Y. Mar. 25, 2024)

Gerber Good Start
Gentle formula isn’t like most other infant formulas, which are made with
“intact” cow’s milk protein. GSG uses cow’s milk protein that has been
partially broken down (“100% Whey-Protein Partially Hydrolyzed”). The FDA
allowed GSG to make “certain specified, modest claims” related to atopic
dermatitis, aka eczema, which is the most common allergic disease in infants.

But the FDA was very
limited in what it allowed: It would not object if Gerber claimed that “little
scientific evidence suggests” that feeding certain infants a “100% Whey Protein
Partially Hydrolyzed infant formula” for the first four months of life “may
reduce the risk of developing atopic dermatitis throughout the 1st year of
life.” The FDA also agreed not to challenge the assertion that “very little
scientific evidence suggests” that the benefits may persist “up to 3 years of
age.”

Gerber then revised GSG’s
packaging to say, among other things, that GSG was the first and “only” formula
“to reduce” an infant’s “risk of developing allergies.”

Previously, NY
and Florida classes were certified
, and there are also individual claims
under New York, Florida, North Carolina, and Wisconsin law.

Here, the court
denied Gerber’s motion for near-complete summary judgment (except Wisconsin
individual claims) and denied plaintiffs’ motion for partial summary judgment, and
also cabined the scope of Gerber’s expert’s testimony.

Plaintiffs alleged
two misrepresentations (1) GSG “reduces the risk of infants developing
allergies.” (2) Implied FDA endorsement, which allegedly occurred when Gerber
“deemphasized” the qualified health claim’s “underwhelming specifics” in its
ads.

First, a safety-seal
sticker on certain GSG canisters stated: “1st & ONLY Routine Formula // TO
REDUCE RISK OF DEVELOPING ALLERGIES // See label inside.” That label, which
could be peeled back before purchase (if you would actually do that in a store)
stated, in part:

Good to know. Our Comfort Proteins® Advantage … If you choose to
introduce formula and have a family history of allergy, feeding a formula
exclusively made with 100% whey partially hydrolyzed, like GOOD START Gentle
formula, during the first four months of life may reduce the risk of atopic
dermatitis* throughout the 1st year, compared to formulas made with intact
cow’s milk protein. The scientific evidence for this is limited and not all
babies will benefit.

The asterisk
following “dermatitis” referred to this statement: “*the most common allergy in
infancy. GOOD START Gentle formula should not be fed to infants who are
allergic to milk or infants with existing milk allergy symptoms. Not for
allergy treatment.”

Magazine ad showing "mommy's eyes, not her allergies" claim

Second, a full-page
print magazine ad that featured an image of a baby’s face with the sentence:
“The Gerber Generation says ‘I love Mommy’s eyes, not her allergies.’ ” Smaller
text below this line, next to an image of a GSG canister, stated:

If you have allergies in your family, breastfeeding your baby can help
reduce their risk. And, if you decide to introduce formula, research shows the
formula you first provide your baby may make a difference. In the case of
Gerber Good Start Gentle Formula, it’s the Comfort Proteins Advantage that is
easy to digest and may also deliver protective benefits. That’s why Gerber Good
Start Gentle Formula is nutrition inspired by breastmilk.

Third, there was a
similar TV ad with “may also” language. (The
FTC did not like these ads either
.)

Plaintiffs alleged
that these ads were false and misleading because there was no scientific evidence
supporting the claim that GSG reduced the risk of developing certain allergies
or atopic dermatitis.

As for the implied
FDA endorsement: (1) A coupon affixed to certain GSG containers described it as
“the first and only formula brand made from 100% whey protein partially
hydrolyzed, and that meets the criteria for a FDA Qualified Health Claim for
atopic dermatitis.” It also bore a gold roundel, featuring the phrase “1st AND
ONLY” surrounded by the phrase “MEETS FDA QUALIFIED HEALTH CLAIM.” (2) A print
magazine advertisement described GSG as the “1st Formula with FDA qualified
health claim.” (3) Another print ad said GSG was “the first and only infant
formula that meets the criteria for a FDA Qualified Health Claim.”

First and only banner ad claim

In fact, the FDA authorizes
health claims only when there is “significant scientific agreement.” It allows
qualified health claims when they are “supported by some scientific evidence” and
accompanied by a disclaimer; the FDA doesn’t approve these claims, but instead
exercises enforcement discretion not to go after them. Crucially, “[t]he
qualified health claim about GSG that the FDA ultimately permitted is not the
claim Gerber originally sought permission to make.” Although Gerber referred to
the qualified health claim determination in its ads, it didn’t use any of the approved
versions.

Gerber’s proposed expert
witness, a pediatric gastroenterologist who worked at Gerber for nearly two
decades, first as the Medical and Scientific Director, then as the Global Chief
Medical Officer, would opine that “Gerber had, and has, a scientifically sound
basis” to represent that “feeding [GSG] instead of intact cow milk protein
formula (CMF) to infants with a family history of allergy in the first month of
life can reduce the risk that said infants will develop allergies, particularly
and specifically atopic dermatitis.” He would further opine that “there is a
significant and substantial body of scientific evidence to support the
representations in the Challenged Advertisements.” “These opinions are, of
course, more forceful than the claims the FDA permitted Gerber to make on the
same subject.”

Plaintiffs’
arguments about bias, lack of data, and prejudice/confusing the jury did not
justify his exclusion, but did justify limiting his testimony. He could be
impeached with his relationship with Gerber. As for inadequate data, his report
was “at base a literature review” considering 20 peer-reviewed publications of infant
trials; he identified four studies as high quality. Three of those reported
that the subjects receiving GSG or its equivalent saw statistically significant
reductions in atopic dermatitis or other allergic diseases for at least a short
time. Other studies showed no reduction compared to ordinary cow’s milk formula,
or at least no statistically significant reduction. A review of medical literature
is generally reliable methodology.

However, it could
not appropriately include “findings that had not been published before Gerber
disseminated the challenged advertisements. … Here, the operative question is
whether Gerber’s challenged ads were misleading when made, not whether they
would be misleading if made today.” Thus, the expert would be limited, when
opining on the science underlying claims in a given ad, “to the body of
research that existed when that advertisement debuted.” But most of the “high
quality” studies would qualify under that restriction. Plaintiffs disagreed
that the studies were “high quality,” but that was an issue for the factfinder.

As to summary
judgment: there was a genuine issue of material fact about whether reasonable
consumers would perceive the ads to claim that GSG could reduce allergy risk.
(Is that not obviously what the ads say, especially the sticker touting: “1st
& ONLY Routine Formula // TO REDUCE RISK OF DEVELOPING ALLERGIES // See
label inside.”?) “Even accepting, arguendo, that the more cabined language on
the ‘label inside’ clarified that GSG does not reduce the risk of developing
allergies, a jury could still find that a reasonable consumer would be left
with that impression.” As to the other ads, the implication was obvious, and a
jury could find it so. (I’m not clear how a reasonable jury could find
otherwise.)

Further, internal
communications showed that Gerber actively endeavored to make an allergy claim
with these ads: Gerber asked its advertisers in a “communications brief” to
“[c]reate a strong link between GSG … [and] an allergy risk reduction
benefit.” Gerber’s marketing team described “being challenged to find ways to
push the envelope with bringing the allergy message forward.” Gerber told its
ad firm that it “would now like to pursue” an ad “that actually uses the word
‘allergy’ in the headline (where previously we were not able to).”

There was also a genuine
dispute of material fact as to whether the “first and only” group of challenged
ads claimed FDA endorsement of GSG. “[A]dvertisements that reframe critiques of
a product as praise can constitute false advertising.”

Gerber argued that
none of the ads explicitly claimed to reduce allergies (uhhh… I do not think
that word means what you think it means) or made FDA-endorsement claims, and
there was no extrinsic evidence about what claims consumers would take away.

But “the requirement
of extrinsic evidence to prove that implied assertions in ads are false is
chiefly a requirement of Lanham Act false advertising claims — claims not
present here.” (And by the way, it has no foundation in the Lanham Act, either.
Courts just made it up as a case-management tool, while imposing a different
rule in TM cases.) “GBL and FDUTPA claims challenging deceptive advertisements
have no extrinsic evidence requirement. Those statutes ‘are not mere Lanham Act
analogues.’”

“The plaintiffs need
not adduce extrinsic evidence of consumer perception to create a jury question
on the deceptiveness element.” (Side note: the individual plaintiffs’ own
testimony should be “extrinsic evidence,” too.) (Extra side note: I know we’re
all textualists now, but maybe this debate would be aided by talking about why
requiring extrinsic evidence, or survey/consumer perception evidence
testimony in particular, would be important.)

However, the
plaintiffs didn’t show as a matter of law that GSG couldn’t

reduce allergy risk. Likewise, whether the FDA statements were false was a triable
issue, though it was a close call: “Gerber
has adduced little evidence to rebut the plain implications of its advertising,
when compared to the qualified health claims that the FDA actually authorized. …
Here, though there is no genuine dispute about whether the FDA ‘endorsed’ GSG,
there is … a lingering dispute about whether Gerber implied such an
endorsement.”

Nor was summary
judgment appropriate for either side on a price premium theory. Plaintiffs’
experts, who used conjoint analysis and similar standard techniques, were not
unquestioned. Under the relevant state laws, “damages need not be calculated by
mathematical precision” but “may include estimates based on assumptions, so
long as the assumptions rest on adequate data.” One of the experts calculated price
premiums in ways that didn’t rely on conjoint analysis, but used internal
Gerber metrics, including its own estimate of the price elasticity of demand, for
the value Gerber would realize from promoting the qualified health claim,
including its projection of 6-10% growth in the United States for the first six
months after introduction of an “allergy claim” to the U.S. market;  Gerber sales forecasts that quantified various
factors, including the “allergy claim,” as “impactors” on future sales; and the
price increases for GSG that Gerber implemented from 2011 to 2014, spanning the
period of these claims.

Gerber’s core
argument was that GSG was priced equal to or below other formulas in the Gerber
Good Start line during the class period, even though these other formulas
undisputedly did not make the challenged claims. But there was also evidence
that Gerber expected to be able to raise prices across “the entire Good Start
portfolio” thanks to the challenged advertising. This was a jury question.

from Blogger http://tushnet.blogspot.com/2024/03/gerbers-good-start-troubles-continue.html

Posted in Uncategorized | Tagged , , | Leave a comment

conjoint analysis has to isolate challenged representations

Moore v.
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, — F.Supp.3d —-, 2024 WL 348821, No:
4:20-cv-09077-JSW (N.D. Cal. Jan. 30, 2024)

The court grants partial
class certification and allows/excludes some expert testimony in this case
alleging that ChapStick products were misleadingly labeled “100% Natural,”
“Natural,” “Naturally Sourced Ingredients,” and “100% Naturally Sourced
Ingredients” when they actually contain non-natural, synthetic, artificial,
and/or highly processed ingredients.

The court allowed the
expert testimony of a survey researcher for a proposed consumer perception
survey and proposed conjoint analysis. Objections to the proposed survey went
to weight, rather than admissibility. Likewise, testimony from an economic
consultant was admissible because it provided additional information about
conjoint analysis, including how it would adequately account for supply-side
factors from an economics standpoint.

However, testimony
of chemists about their view of what constituted an “artificial” ingredient
wasn’t relevant: “Here, the only relevant understanding of the Challenged
Statements is that of the reasonable consumer.” Both parties’ chemists were
excluded.

Skipping over a lot,
could materiality be proved on a classwide basis? As previous cases indicate, “[m]ateriality
can be shown by a third party’s, or defendant’s own, market research showing
the importance of such representations to purchasers.” Defendants’ documents
and testimony acknowledge that there is a “strong consumer desire for ‘natural’
products and ingredients” in the lip balm market generally. Internal marketing
research concluded that the “100% Naturals” ChapStick products “[t]ap[ ] into
consumer desire for [a] natural option,” finding “79% of lip balm users 18-34
[are] interested in [the] natural option.” The same percentage of consumers
identified ingredients as an “important” product-attribute; 59% of consumers
also identified how ingredients are sourced; and 57% identified that where
ingredients are sourced is “important.” Defendants’ other surveys rendered
similar results: one found “ ‘Natural’ is important in a product that promises
more than color and another found 65% of consumers place “importance” on
“[a]ll-natural ingredients.” This was enough to create common evidence of
materiality to a reasonable consumer.

However, a proposed
consumer perception survey didn’t separately establish common proof of
materiality. It failed to sufficiently isolate the challenged statements,
combining the “natural” terms with extraneous words such as “Lip Butter,” “Natural
with Argan Oil,” “Natural Age Defying,” etc. But the proposed survey was not
impermissibly leading merely because it asked “whether or not they understand
the specified statements on the product packaging to be communicating certain
meanings.”

Failure to isolate the
challenged statements in the proposed conjoint survey also made it incapable of
calculating a reliable price premium; the court suggested that it could grant damages
class certification on a renewed motion if there were a method that isolated
the challenged statements.

There was standing
to seek injunctive relief because the plaintiff still desires to buy natural
lip-care products and would like to buy them again, but doesn’t know whether
they are, in fact, natural, and she does not have the expertise to discern from
their ingredient disclosures whether the Challenged Statements are true.

from Blogger http://tushnet.blogspot.com/2024/03/conjoint-analysis-has-to-isolate.html

Posted in Uncategorized | Tagged , , , | Leave a comment

disclaimers that require consumers to understand tech, history and law don’t avoid lawsuit over “flushable”

Schotte v. Stop
& Shop Supermarket Co., 2024 WL 1251284, No. 1:23-cv-10897-IT (D. Mass Mar.
22, 2024)

Stop & Shop allegedly
deceptively advertised cleansing wipe products as “flushable” in violation of
Mass. Gen. Laws ch. 93A; Schotte also brought warranty, unjust enrichment, and
fraud claims. The court declined to dismiss the complaint.

The Stop & Shop Wipes, which vary in fragrance and style, are all
marketed and sold with bold, prominent font labeling them as “flushable” on the
front of the packaging. Following the word “flushable” on the front of all
packaging is a “†”and the text “For flushing see [back or bottom] panel” in
smaller print. The back or bottom panel sets forth the following statements in
even smaller print:

Independent lab testing shows these wipes meet INDA Flushable Product
Guidelines. Not all systems can accept flushable wipes. Ignoring Disposal
Instructions may lead to clogs, property damage, or regulatory violations.

DISPOSAL INSTRUCTIONS

Do not flush if:

• Violates local rules.

• Using RV, marine, or aviation system.

• Using macerator toilet or household pump.

• Fat or grease are put in any drain or you are unsure of system
capability

Flushing ok if:

• Permitted by local rules.

• One wipe per flush.

• No history of clogs or backups.

• Septic follows EPA schedule for alternative systems (annual
inspection & pumping).

If a problem is noticed, dispose of in trash and stop flushing.

The remainder of the
disclaimer is concealed by a tab; the concealed portion reads, in part, “not
all systems can accept flushable wipes.”

Schotte alleged a
“substantial price premium” of at least 25% more for the Wipes as compared to
non-flushable wipes from the same brands. Schotte also alleged that the wipes
are not in fact flushable because they do not “break apart or disperse in a
reasonable period of time after flushing, resulting in clogs or other sewer
damage.”

Stop & Shop
argued that this couldn’t deceive a reasonable consumer, both because of the
disclaimers and because flushable merely means “capable of being flushed down a
toilet,” regardless of what happens later on. (That’s not my department!)

“[W]hether a term
with multiple, contradictory definitions or interpretations has the capacity to
mislead is best left to ‘six jurors, rather than three judges, [to] decide on a
full record.’” To avoid a finding of plausible deceptiveness, disclaimers or
qualifications must be “sufficiently prominent and unambiguous …. Anything
less is only likely to cause confusion by creating contradictory double
meanings.” Here, a factfinder

could reasonably find that the disclaimer on the back of the Wipes
packaging is neither sufficiently prominent nor unambiguous and, instead, that
the small-print lists would not be noticed. And a factfinder could also find
that even if the lists were noticed, the disclaimers would require consumers to
have in-depth knowledge of the sewer or septic system they are using, its
plumbing history, as well as “local rules”—not just for a toilet in their
residence or office but any toilet they may wish to dispose of the Wipes in. A
reasonable jury could find the disclaimer so small and vague that it does not
relieve Defendant of any potential liability for its deceptive acts.

In addition, Schotte
alleged that he would be interested in purchasing the wipes again if Stop &
Shop ensured they were actually flushable, so he sufficiently pled a likelihood
of future injury to establish standing for injunctive and declaratory relief.

Side note: one court
has held that “flushable” is not sufficiently factual/uncontroversial to allow legislatively
required disclosures under Zauderer. I think that’s definitely wrong,
but it’s consistent with a pattern where courts allow themselves—or juries they
supervise—to find facts but don’t like legislatures doing so. Both courts and
legislatures are governmental regulators, though.

from Blogger http://tushnet.blogspot.com/2024/03/disclaimers-that-require-consumers-to.html

Posted in Uncategorized | Tagged , | Leave a comment

adult venue’s insurer did not successfully exclude ads from ad injury coverage

Princeton Excess &
Surplus Lines Ins. Co. v. R.I. Cranston Entertainment Inc.; 2024 WL 1285631, C.A.
No. 21-63-JJM-PAS (D.R.I. Mar. 26, 2024)

Defendant, d/b/a
Wonderland, operated an adult entertainment club and was one of the many such
sued by various models for using their images in advertising without their
consent from 2015 to 2019. Princeton insured Wonderland from 2016-2018 (with a
broad exclusion for defamation, invasion of privacy, and various forms of
advertising injury in the second year called the Exhibitions and Related
Marketing Exclusion), and agreed to defend the club but reserved the right to
deny insurance coverage. After settlement negotiations (including Wonderland’s
separate counsel), Wonderland agreed to a judgment for $1.895 million, with a
covenant not to execute and an assignment of rights against Princeton to the
models in lieu of payment. Princeton then sued Wonderland and the models,
seeking a declaratory judgment that it has no obligations under the Consent
Judgment. Defendants counterclaimed for payment and damages for breach of
contract and bad faith.

If policy terms are
“ambiguous or capable of more than one reasonable meaning, the policy will be
strictly construed in favor of the insured and against the insurer.”

Princeton argued
that (1) no coverage was available for claims during the 2017 to 18 Policy
Period; (2) Wonderland breached the insurance contract by agreeing to the
Consent Judgment in violation of the cooperation and non-assignment clauses;
and (3) the Consent Judgment was unreasonable, and thus unenforceable, as a
matter of law.

The consent judgment
was a lump sum and, Princeton argued, included uncovered claims; most of the images
fell within the 2017-18 period. The policy excluded personal and advertising injury,
including “publication, in any manner, of material that violates a person’s
right of privacy,” disparagement, use of advertising ideas, and trade dress
infringement, if such activities “arise out of or are part of ‘exhibitions and
related marketing,’ ” which are broadly defined.

The underlying claim
alleged false advertising and false association under the Lanham Act,
misappropriation, violation of the Models’ common-law and statutory privacy
rights, and defamation, “all of which fall squarely under Personal and
Advertising Injury. So the burden falls to Princeton to show that its exclusion
is valid.”

The problem was that
the policy and the exclusion were “clearly worded, specific, and directly
contradictory to each other. Under Rhode Island law, policy exclusions must be
unambiguous, and ‘contract provisions subject to more than one interpretation
are construed strictly against the insurer.’” Also, “Rhode Island courts will
not uphold an exclusion that leads to unreasonable results, particularly if
doing so will make another part of the coverage illusory.” The court found that
definition of “Exhibitions and Related Marketing” was so broad as to “preclude
coverage in almost any circumstance.” The Fifth Circuit recently found that,
even if all “advertising injury” was excluded by this exact policy language, “personal
and advertising injury” was an umbrella provision and not illusory because
there was still personal injury coverage. Princeton Excess & Surplus Lines
Ins. Co. v. A.H.D. Houston, Inc., 84 F.4th 274 (5th Cir. 2023); but see Princeton
Express v. DM Ventures USA LLC, 209 F. Supp. 3d 1252, 1258 (S.D. Fla. 2016) (declining
to uphold a “field of entertainment” exclusion on the grounds that it would
exclude “anything listed in (d) through (g) listed under Personal and
Advertising Injuries” and would thus make the Policies illusory as to
advertising coverage).

The court here
disagreed with the Fifth Circuit. By its plain language, “exhibitions”
encompass almost all forms of production and advertising: “motion pictures,
television programs, commercials, web or internet productions, theatrical
shows, sporting events, music, promotional events, celebrity image or likeness,
literary works and similar productions or work ….” including social media, as
well as material produced “in any medium including videos, phonographic
recordings, tapes, compact discs, DVDs, memory cards, electronic software or
media, books, magazines, social media, webcasts and websites”— “a broad-ranging
definition that contradicts Princeton’s purported coverage” for “advertising”
(defined as “a notice that is broadcast or published to the general public …
about your goods, products or services”). And the exclusion also withdrew
coverage for all related forms of marketing. Rhode Island doesn’t allow
insurers to make whole sections of a policy illusory.

It also didn’t save
Princeton that exceptions purportedly restored coverage for advertising related
to Wonderland’s food and liquor services. Princeton argued that these
exceptions preserve coverage for “use of another’s advertising idea or
infringement of copyright, slogan, or trade dress in an advertisement for any
aspect of Wonderland’s business other than exhibitions or marketing for
exhibitions (such as its food or liquor service).” “But the Exhibitions and
Related Marketing Exclusion precludes coverage for any commercial, web
production, or promotional event, regardless of whether the advertisement
relates to a show, a theatrical performance, or purchase of a hamburger. It
would exclude the advertising examples that Princeton cites to make its case.”

Thus, Princeton owed
Wonderland a duty to indemnify for advertising injury arising out of
Exhibitions and Related Marketing under the 2017 to 18 Policy. Moreover, there
was no evidence that the consent judgment purported to settle claims outside
the policy period; it was based on Princeton’s denial of claims for that
period, and its plain language suggested that it was limited to that period.

The policy didn’t apply
to “[a]ny punitive damages, exemplary damages, or the multiplied portion of any
award, because of any ‘bodily injury’, ‘property damage’ or ‘personal and
advertising injury’.” But again, there was no evidence that the consent judgment
included these.

Princeton argued
that Wonderland breached the terms of the insurance contract by interfering
with its right to defend and settling the case in violation of the cooperation
and non-assignment clauses. But it was uncontested that Princeton knew about
the Models’ offer and took no steps to preserve its rights over the course of
many months, so it waived any objection to the terms of the settlement. Also,
there was a cooperation clause requiring cooperation in investigation and
settlement; this is a reciprocal obligation, and no reasonable jury could look
at Princeton’s conduct and find that it used “reasonable diligence” to obtain
Wonderland’s cooperation.

Finally, Princeton
waived its right to object based on the non-assignment clause:

We think the insured should be allowed, as soon as the insurer denies
coverage, to protect its interest by negotiating a settlement. The only
valuable asset the insured may have is its cause of action against the insurer
and the insured should be able to assign this right to the injured party to
protect itself from further liability.

Also, “because an
insured’s rights to proceeds vests at the time of loss … restrictions on the
insured’s right to assign its proceeds are generally rendered void.”

Was the consent
judgment collusive and unreasonable and thus unenforceable? No, there was no
evidence of misconduct. (Princeton was bound because the judgment fixed
Wonderland’s liability, triggering the duty to indemnify, and Wonderland
properly assigned its claims to the models.) Princeton pointed to statements
made by Wonderland’s manager, who stated that the offer of $10,000 per model
was “crazy” and was upset that Princeton “did not want to fight it.” It argued
that this was incompatible with Wonderland’s decision to settle all claims for
$1.895 million, and that the manager hadn’t read the consent judgment so
Wonderland could not have truthfully stated that it was reasonable.

“That a party may
have opposed a settlement does not render a settlement fraudulent or collusive.
And a party’s failure to read a contract does not render it unenforceable. A
party may rely on their attorney in drafting settlement documents, and the
attorney can be presumed to speak for them regardless of whether they have read
the documents.” Any concerns about collusion were “further assuaged by the fact
that the judgment was negotiated under the supervision and guidance of a
seasoned Magistrate Judge and that other courts have repeatedly found liability
on similar facts.”

But the complaint included
other policy exclusions that were not yet before the court (exclusions for
knowing falsity and the like), so defendants only got partial summary judgment.
 They were entitled to summary judgment
on liability for breach of contract (the duty to indemnify), but not on
damages.

from Blogger http://tushnet.blogspot.com/2024/03/adult-venues-insurer-did-not.html

Posted in Uncategorized | Tagged , , | Leave a comment

5th Circuit allows image-based tobacco warnings in barest nod to consistency on compelled commercial speech

R J Reynolds Tobacco
Co. v. Food & Drug Admin., 2024 WL 1208111, — F.4th —-, No. 23-40076 (5th
Cir. Mar. 21, 2024)

The sudden shift in the political valence of the
commercial speech doctrine

strikes again! The Fifth Circuit upholds mandatory cigarette warnings as
acceptable compelled commercial speech under Zauderer, reversing the
district court’s 2022 decision. Let’s just say that, five years ago, this would
have struck me as an unlikely result, and in 2020 the decision to file in Texas
would have been much less complicated; even in 2022, I would have expected the
district court to be upheld. (It returns to the district court for an APA
challenge, about which I express no opinion.)

The Family Smoking
Prevention and Tobacco Control Act requires cigarette packages to include
“color graphics depicting the negative health consequences of smoking to
accompany the [updated] label statements.” These warnings “shall comprise the
top 50 percent of the front and rear panels of the package” of cigarettes and
“at least 20 percent of the area of [any] advertisement ….” A facial
challenge was rejected by the Sixth Circuit in 2012, but the DC Circuit struck
down the FDA’s first attempt on an as-applied challenge. Now it’s the 5th
Circuit’s turn.

In enacting the TCA,
Congress found that “efforts to restrict advertising and marketing of tobacco
products,” including existing mandatory warnings, had “failed adequately to
curb tobacco use by adolescents, [so] comprehensive restrictions on the sale,
promotion, and distribution of such products [were] needed.” The TCA’s
legislative findings included: (1) minors still often see and are exposed to
tobacco product advertising; (2) the “overwhelming majority of Americans who
use tobacco products begin using such products while they are minors and become
addicted to the nicotine in those products before reaching the age of 18” and
(3) “[r]educing the use of tobacco by minors by 50 percent would prevent well
over 10,000,000 of today’s children from becoming regular, daily smokers,
saving over 3,000,000 of them from premature death due to tobacco-induced
disease[s]” and would “result in approximately $75,000,000,000 in savings
attributable to reduced health care costs.”

Congress identified
nine new warnings to rotate regularly, which must “comprise the top 50 percent
of the front and rear panels of” each cigarette package and “at least 20
percent of the area of [any] advertisement ….” It further instructed the
Secretary of Health and Human Services to “issue regulations that require color
graphics depicting the negative health consequences of smoking to accompany the
label statements.” And Congress gave the Secretary the authority to “adjust the
type size, text and format of the label statements” for clarity,
conspicuousness, and legibility.

When the FDA made
its first attempt, the DC Circuit held that the chosen graphics were not
targeted at deception; nor were they providing “‘purely factual and
uncontroversial’ information” because the images “could be misinterpreted by
consumers” and “are primarily intended to evoke an emotional response, or, at
most, shock the viewer into retaining the information in the text warning.” It
therefore applied Central Hudson instead of Zauderer and struck
down the initial rule. Under Central Hudson, the FDA lacked even
“a shred of evidence … showing that the graphic warnings will ‘directly
advance’ [FDA’s] interest in reducing the number of Americans who smoke.”

The FDA reasoned
that its new images promoted “the Government’s interest in promoting greater
public understanding of the negative health consequences of cigarette smoking”
and also “dissipat[es] the possibility of consumer confusion or deception,”
thereby advancing the government’s interest in preventing “consumer
misperceptions regarding the risks presented by cigarettes.”

Warnings with images, such as "smoking cases head and neck cancer" with image of woman with obvious neck swelling

Plaintiffs here alleged
that each of the Warnings “misrepresent[s] or exaggerate[s] the potential
effects of smoking” and that, “[c]ontrary to FDA’s characterization, the peer
reviewers raised serious, substantive concerns about FDA’s studies” used to
support the selected Warnings.

The district court
reasoned that Zauderer did not apply because the imagery was
fundamentally so “prone to ambiguous interpretation” that “it is unclear how a
court would go about determining whether it[ ] … is ‘accurate’ and ‘factual’
in nature”:

In other words, the court reasoned that no photorealistic image could
ever be purely factual and uncontroversial because different viewers will
ascribe to it different meanings. The inherent ambiguity in any graphic
warning—e.g., that viewers may interpret the heart disease warning to suggest
that open-heart surgery “is the most common treatment for heart disease” or the
best—means that the Warnings cannot be “ ‘purely factual and uncontroversial’
and objectively accurate as required to allow relaxed Zauderer review.”
Further, the court found that the graphic portions of the Warnings fell beyond Zauderer’s
reach because they are inherently “provocative.”

And the warnings
weren’t narrowly tailored under Central Hudson
because the
government hadn’t first tried increased
funding for antismoking advertisements, increased government anti-smoking
communications, or “test[ed] the efficacy of ‘smaller or differently placed
warnings.’ ”

(Preclusion as to
RJR’s challenge to the constitutionality of the TCA itself would have been
appropriate, but that didn’t resolve the case (there were other plaintiffs), so
the court proceeded to the merits.)

Key holding: “The
Warnings are both factual and uncontroversial, despite the emotional impact the
graphics may have.”

The court—weighing
in on an issue that
divided the DC Circuit—concluded that Zauderer is a “carve-out” from, not an
application of, Central Hudson.

Moreover (and not
unrelatedly), Zauderer
applies to all compelled commercial
speech, not just deception-preventing speech. The Fifth Circuit held in NetChoice
that the state’s interest in “enabling
users to make an informed choice regarding whether to use [social media]
Platforms” was sufficient to survive review under Zauderer. Similarly, Chamber
of Commerce of the USA v. SEC, 85 F.4th 760 (5th Cir. 2023), recently held that
“the disclosure of a company’s rationale for a stock buyback was purely factual
and uncontroversial commercial speech” (although it still struck down the SEC’s
action because it was the SEC, I mean because of the APA).

First, the warnings
were “purely factual.” What is factual? Well, it’s not an opinion. Moreover,
the government may not demand a private party “undertake contextual analyses,
weighing and balancing many factors … that depend on community standards,” to
determine the speech it must “parrot.” Book People, Inc. v. Wong, 91 F.4th 318,
340 (5th Cir. 2024). “Factual” needs to involve “information” that is “[c]oncerned
with what is actually the case rather than interpretations of or reactions to
it” and “actually occurring.” (Lots of dictionaries invoked here.) Thus,
“factual” must mean “falsifiable material and inferences fairly drawn from it,
rather than one’s non-falsifiable ‘interpretations[,] … reactions,’ or
opinions.”

Crucially, “factual”
does not mean “true,” because that would make “purely factual information”—the
language of Zauderer—surplusage. (This seems to ignore the idea that
opinions aren’t statutes, but here we are.) Thus, the required warnings would
be factual if they were comprised of “only (a) information supported by facts
and (b) conclusions driven by those facts, and (2) not akin to unfalsifiable
statements of opinion.”

Plaintiffs argued
that the new warnings “misleadingly exaggerate smoking risks” and improperly
“focus on conditions that less frequently arise from smoking,” even though the
existing warnings were concededly purely factual. “Consequences supported by
scientific findings, even if exaggerated or non-modal, are still, by
definition, factual.” The factual content of the text
was
undisputed.

What about the images? Images can be factual. “The addition of images to the textual
warnings makes no difference to the constitutional analysis of factuality.” In
the FDA’s own words: “FDA used a certified medical illustrator to design images
that depicted common visual presentations of the health conditions and/or
showed disease states and symptoms as they are typically experienced, and that
present the health conditions in a realistic and objective format devoid of
non-essential elements.” Each of the images was “a straightforward,
science-based, objectively truthful depiction of the accompanying text,” “no
different from those a medical student might see in a textbook.”

Merely because the
images might convey “an ideological or provocative message” does not make them
nonfactual:

A fact does not become “value-laden” merely because the fact drives a
reaction. But even if it did, ideological baggage has no relevance to the first
Zauderer prong. Any number of factual messages are, of course,
ideological. Similarly, emotional response to a statement is irrelevant to its
truth. That someone may have to declare bankruptcy [in order to get debt
relief] is likely to engender strong emotions. But the Court never even
discussed that aspect of the mandatory disclosures [in its case upholding required
disclosures about bankruptcy by certain debt relief providers].

[Footnote] … We offer the following example: “The Nazis committed
genocide.” That is a factual statement. It is also a statement that denounces
the Nazi’s actions and beliefs as morally repugnant. That is an ideological
message. Though the government may not be able to compel Volkswagen to include
that message in its advertising without justification, a court would likely
still review any such attempt under Zauderer.

[Somebody is
thinking about abortion disclosures.]

Plus, these images
were “meant to be interpreted literally.” They weren’t “primarily intended to
evoke an emotional response” but instead “to draw attention to the warning and
depict a possible medical consequence of smoking. Thus, at most, the emotional
response of viewers is incidental to their retention of information about the
health risks.”

What about the
argument that the images might be subject to several different interpretations,
and the FDA didn’t test for consumer takeaway? “[W]hen each image is paired
with a fact-based, textual warning, any reasonable viewer interprets the image
in light of the words.” It was error to ignore the words.

Also, the government
need not choose only the most common side-effect or consequence of the disease
or injury discussed in a warning. “People may interpret ‘debt relief agency’ in
many ways, but disclosing that a business is one is still purely factual.” Nor
were cigarette companies required to make difficult contextual judgments
weighing multiple factors to determine the warning, since the FDA did it for
them.  

For similar reasons,
the warnings were uncontroversial. NIFLA
says that abortion is a
controversial topic, making disclosures about abortion controversial; but NetChoice
said that “disclosures of social media
censorship decisions” were not controversial. Thus, a factual disclosure is
“controversial” under Zauderer “where the truth of the statement is not
settled or is overwhelmingly disproven or where the inherent nature of the
subject raises a live, contentious political dispute.” Content moderation isn’t
inherently
contentious, even though it was connected to “a live, contentious, political issue.” [Wow,
this might be even dumber than the statements in NetChoice

itself. Because it is about content that some people want and some people
don’t, content moderation policy is the definition of inherently contentious—as
abortion is not, even if people living in Texas today think it must be. This is
a fake argument; the real reason—inconsistent with NIFLA’s dicta, which
should be ignored the way all abortion-related First Amendment pronouncements
should be ignored—comes next.]

There’s no good-faith debate that the warnings aren’t
truthful. Thus, they are uncontroversial.

Next, the warnings
must be “reasonably related to the State’s interest” and not “unjustified or
unduly burdensome.” “Zauderer does not require the state to assert an
anti-deception interest.” No court of appeals majority has ever held otherwise,
and the Fifth Circuit has previously referred to valid interests in “promoting
the free flow of commercial information”; we ruled that was “more than enough
to satisfy this prong of Zauderer” and “promoting the ethical integrity
of the legal profession.” “Increasing public understanding of the risks of
smoking, particularly given the ‘long history of deception concerning consumer
health risks in the cigarette industry,’ is a legitimate state interest.” [Now
do the long history of state and private discrimination against nonwhites.]

The warnings were
not unjustified. Plaintiffs argued that the interest at issue was too amorphous
and that the warnings hadn’t been shown to be effective.

The images served an
informational interest. Zauderer
itself explained that “[t]he use of illustrations or pictures in
advertisements serves important communicative functions: it attracts the
attention of the audience to the advertiser’s message, and it may also serve to
impart information directly.” The FDA even tested their effectiveness in
raising consumer awareness and then refined them based on those results.

NIFLA says that a compelled disclosure is
justified only if it will “remedy a harm that is ‘potentially real[,] not
purely hypothetical,’ and … ‘extend[s] no broader than reasonably necessary.’
” Plaintiffs argued that current Surgeon General’s warnings are sufficient, but
that ignored “significant evidence that consumers do not notice, much less
internalize, the text-only warnings in the status quo. The updated warnings
serve to remedy the harm that buyers might (1) not know about tobacco’s harms
or (2) ignore the existing Surgeon General’s warnings.”

And here the Fifth
Circuit engages in what is all too common in rejecting plaintiffs’ arguments:
it makes up a contradiction that doesn’t exist. This isn’t to say the Fifth
Circuit is wrong about the weighing here, but it’s a bad look to claim logical
flaws that are themselves illogical: “Plaintiffs inconsistently claim that the
disclosure requirements are overly emotional and ideological such that they
become non-factual speech, while also asserting that FDA’s informational
interest does not justify the Warnings because they will not be effective. In
other words, plaintiffs suggest consumers will simultaneously notice and not
notice the warnings.” But of course, consumers could both notice

and not be informed or change their behavior because of the warnings. I
notice a ton of stuff to which I am indifferent every day. The underlying
question is whether the government ought to have to show some real likelihood
of changed decisionmaking in order to justify mandatory disclosures, and I have
to admit that I am leaning more towards “yes,” at least for a noticeable
percentage of consumers. In the absence of any need for effectiveness,
disclosure becomes a compromise where regulators/lawmakers tell themselves
they’re protecting consumers while blaming the ones who continue to make “bad”
decisions for the consequences of continued marketing.

Effectiveness:
Plaintiffs argued that the FDA’s studies were flawed, but all that was required
constitutionally was a reasonable relation to a legitimate state interest. “Whether
FDA’s use of the studies survives APA review is a question we consider separately
from our Zauderer review.” This move too sets up the ability to approve
state mandates (not subject to the APA) like in NetChoice
while
still invalidating anything the Fifth Circuit doesn’t like as a policy matter.

The warnings were not unduly burdensome, despite their size
and offputting content. Even if they wouldn’t survive Central Hudson
review, that wasn’t enough to invalidate them. The Sixth Circuit already upheld
the required size and the court here wasn’t going to revisit that. “Undue
burden” means that “the regulation
cannot impose a burden excessive or disproportionate to the benefits gained.”
In NIFLA, the burden was undue because the disclosures were “wholly
disconnected from California’s informational interest”; allowed for no
consideration of “what the facilities say on site or in their advertisements”;
and “cover[ed] a curiously narrow subset of speakers.” But in NetChoice,
decision disclosure/appeal and biannual transparency disclosure couldn’t
possibly burden protected speech, so that was ok, and the SEC’s buyback
disclosures weren’t unduly burdensome because they “neither burden[ ] issuers’
protected speech nor drown[ ] out their message” given that they occurred only
“within the narrow confines of SEC filings.” [Gotta admit, these don’t sound
promising for disclosures that have to be a big part of every package.]

Here, the benefits
were to alleviate “information asymmetry regarding the harms tobacco causes and
consumers’ suboptimal awareness of and response to those harms,” and reducing
those harms would be a significant benefit. [If it occurs.]

The claimed harms
were to plaintiffs’ free speech rights and to their finances. But “plaintiffs
can still speak on 80% of their advertisements, and they still control more
than 50% of the total surface area of their cigarette packages.” That allowed “ample
room for manufacturers to distinguish their products from other products” and
not be “drown[ed] out” or deterred from advertising at all. And plaintiffs have
at most a “minimal” interest in withholding useful and factual information;
harm suffered from an infringement on that interest was limited. Thus, the
burdens were not undue in comparison to the benefits.

from Blogger http://tushnet.blogspot.com/2024/03/5th-circuit-allows-image-based-tobacco.html

Posted in Uncategorized | Tagged , , | Leave a comment

Nominative fair use requires D to prevail on all 3 factors in 9th Circuit, district court concludes

Axon Enterprise,
Inc. v. Luxury Home Buyers, LLC, — F.Supp.3d —-, No.: 2:20-cv-01344-JAD-MDC
(D. Nev. Jan. 16, 2024)

The court grants plaintiff’s motion for
reconsideration of parts of this case, discussed
previously
. Axon alleged that LHB infringed Axon’s “Taser” mark. The court
previously denied summary judgment on nominative fair use, treating it as a
balancing test: LHB needed to use “Taser” to refer to Axon’s product, but used
too much (it was a former distributor), and there were genuine disputes of fact
on whether it did anything else to suggest endorsement. The court granted
reconsideration, now holding that all three prongs weren’t satisfied. Although
what constitutes “too much” varies based on circumstance—an artist may need to
use Barbie’s name and trade dress to make Barbie-themed art—the “no more than
necessary” element needs to be satisfied to allow the defense to foreclose
further consideration of confusion.

Thus, here, LHB used
more of the Taser mark than necessary when it used its distinctive lettering
and logo, and Axon was entitled to summary judgment in its favor on
infringement. However, whether the permanent injunction already entered to “bar
LHB’s use of Axon’s Stylized Taser Mark and Logos on all its websites and
advertising” should be modified raised First Amendment considerations that required
further briefing. (I take it this means that the logic of NFU means that remedies should allow proper NFU rather than flat bans.)

from Blogger http://tushnet.blogspot.com/2024/03/nominative-fair-use-requires-d-to.html

Posted in Uncategorized | Tagged , , | Leave a comment